Skip to content
‹ Back to IndustriesSciences

Elon Musk Successfully Launches the Falcon Heavy Rocket

Elon Musk has made it his life mission to take humankind to space. On February 6th, he got even closer to achieving that goal when his company SpaceX launched the historic maiden voyage of its Falcon Heavy Rocket, putting a Tesla Roadster into orbit, and landing two rocket boosters back on Earth. After a brief…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Sciences · · Promoted Content
Share
Elon Musk Successfully Launches the Falcon Heavy Rocket

Key takeaways

01

Elon Musk has made it his life mission to take humankind to space.

02

On February 6th, he got even closer to achieving that goal when his company SpaceX launched the historic maiden voyage of its Falcon Heavy Rocket, putting a Tesla Roadster into orbit, and landing two rocket boosters back on Earth.

Free workspace

Turn your Sciences expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

Elon Musk has made it his life mission to take humankind to space. On February 6th, he got even closer to achieving that goal when his company SpaceX launched the historic maiden voyage of its Falcon Heavy Rocket, putting a Tesla Roadster into orbit, and landing two rocket boosters back on Earth. After a brief two-hour delay, the launch departed from Kennedy Space Center in Cape Canaveral, Florida—the same location from which NASA’s Apollo moon missions and space shuttles departed from.

The rocket itself is impressive. It stands at a massive 23 stories tall and is powered by 27 engines on three core boosters, which produces 5 million lbs. of thrust at liftoff. SpaceX, ever the innovator in composite applications, engineered the rocket’s payload fairing with a composite structure and carbon fiber face sheets that were manufactured in-house. It’s built to protect satellites during delivery to low-Earth orbit as well as geosynchronous transfer orbit.

That Tesla Roadster is something to see as well. Equipped with a mannequin named “Starman” after the 1972 David Bowie song, and a dashboard message of “Don’t Panic!” from the book Hitchhiker’s Guide to the Galaxy by Douglas Adams, the cherry red convertible is currently on a trajectory taking it past Mars, and on its way to orbit the sun. You can watch footage of it here.

After the success of the launch, two of the core boosters, designed to be reusable, returned to their designated areas in Cape Canaveral Air Force Station. The third was set to land on a landing pad in the Atlantic Ocean. It missed—taking out a drone ship nearby, and plunging into the water at 300 miles per hour. Despite this miscalculation, the test run was still a huge success for the future of space exploration and space travel.

“I think it’s going to open up a sense of possibility,” Musk was widely reported to have said after the launch. “We want a new space race. Space races are exciting.”

SpaceX is ready to lead the charge. With the success of the test run, the next steps include commercial satellite launches for the U.S. Air Force and a solar-sail mission for The Planetary Society. After that, SpaceX wants to send people to Mars as early as 2024.

“Crazy things can come true,” Musk added. “When I see a rocket lift off, I see a thousand things that could not work, and it’s amazing when they do.” Some of those amazing things working where they shouldn’t are undoubtedly because of the use of composites.

Magnum Venus Products is an innovator of composites, pumping and spraying equipment for closed/open molds, adhesives, and epoxies. MVP serves a multitude of manufacturers in a variety of industries such as automotive, aerospace, transportation, marine, railway, and oil & gas among many others. For more information on the great products MVP offers, visit the website!

Read more at mvpind.com

Your experts belong here

Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.

Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

Book DemoSee how it works15 minutes, straight to a calendar.

About the author

S
Sciences
B2B Weekly

The week in Sciences, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Sciences expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your lab directors, applications scientists, and field specialists into the articles, video, and social content Sciences buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Sciences Insights

Antibody developability checks are moving into discovery instead of waiting for development

Antibody developability checks are moving into discovery instead of waiting for development

Maria Gonzalez-Pajuelo of FairJourney Bio says the order in antibody discovery is changing: developability has become a much more important consideration during discovery, rather than an issue left until later-stage development. The goal, she says, is that what comes out of discovery is something CMC can take forward easily.

  • 01Discovery-stage developability screens can rank many antibodies tested once or twice and may reduce surprises later in development, while development still focuses on several lots of a single antibody and answers different questions.

Oct 1, 2026

Caraballo expects AI across all five tracks at ISPE’s 2026 Annual Meeting

Caraballo expects AI across all five tracks at ISPE’s 2026 Annual Meeting

ISPE’s 2026 Annual Meeting and Expo in Washington, DC organizes its program around five tracks running from discovery to governance, with international program committee chair Connie Langer of Pfizer Global Supply and executive chair Jose Caraballo of JCO Global Advisory LLC describing how the tracks connect—and why AI is treated as a cross-cutting topic rather than a standalone track. Deloitte’s December 2025 survey of 280 executives frames the mood the program is built for.

  • 01ISPE’s 2026 Annual Meeting has no dedicated AI track; executive chair Jose Caraballo expects AI presentations across all five tracks, from discovery to governance.
  • 02Deloitte’s December 2025 survey of 280 biopharma and medtech C-suite executives found more than 75% confident in their own outlook but only 41% optimistic about the global economy, a mood the story says the ISPE chairs are programming for.
  • 03A staffing firm reports life sciences job openings falling even as digital fluency becomes a required skill, so the upskilling burden lands on the people already employed, which is where the mandatory, university-partnered AI training Connie Langer describes at her company sits.

Sep 30, 2026

Crown Bioscience's San Diego site fits the tumor model to the therapy, not the reverse

Crown Bioscience's San Diego site fits the tumor model to the therapy, not the reverse

Crown Bioscience's San Diego site designs preclinical tumor models to match specific therapies and delivery routes, rather than forcing treatments into standard study designs. It combines custom surgical procedures, cell line-derived xenografts, patient-derived xenografts (including post-treatment models), and biomarker capabilities to generate translational data that can help sponsors decide whether to advance a program.

  • 01Orthotopic brain tumor implantation using tagged models lets researchers track tumor growth in the original organ, aligning the model and delivery route with how therapies are intended to be tested.
  • 02Patient-derived xenografts developed from tumors after prior treatment may better reflect progressed disease, helping teams study therapies aimed at patients whose cancer has advanced after earlier treatment.
  • 03Combining biomarker analysis of preclinical model samples with clinical sample testing at one site could make it easier to connect what is measured in animals with what is later measured in patients.

Sep 30, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

S
Sciences

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512